Johnson & Johnson may resume corona vaccine study in US

ABM FN-Dow Jones –
Saturday, 24 October 2020 1:16 PM

Johnson & Johnson may soon resume Phase 3 research with a potential corona vaccine as no evidence has been found that the vaccine has caused serious medical problems in a subject. This became known on Friday evening.

Earlier this month, subsidiary Janssen Vaccines stopped all studies on the vaccine when it appeared that one of the participants had an unexplained disease.

In September, a major Phase 3 research study of the vaccine began, involving a total of 60,000 subjects in the United States and a number of other countries.

J&J said Friday that an independent committee has been advised to resume the study in the US. Consultations are being held with regulators in other countries to restart vaccine studies there as well.

The group did not provide further details on the subject’s medical issue. According to J&J, a concrete cause has not been found.

It was announced separately on Friday that AstraZeneca in the US can also continue with its corona vaccine study.

Share on facebook
Share on pinterest
Share on twitter
Share on linkedin
Share on email


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.